



# Bal Pharma Limited

1) The Manager-Listing

07.02.2017

National Stock Exchange of India Ltd  
Mumbai.

2) The Manager-Listing

BSE Ltd  
Mumbai.

**Dear Sir,**

**Sub : Out Come of the Board Meeting.  
Ref : Regulation 33 of SEBI(LODR) Regulations, 2015.**

As already informed to the exchanges, Board of Directors of the Company has met today and *inter alia* transacted the following business;

- a) Approved the Un-audited stand alone and consolidated financial results of the Company for the quarter and nine months ended 31.12.2016.

A copy of the approved financial results along with Limited Review report issued by the statutory auditors of the Company is enclosed with this intimation.

Please take this intimation on record.

**For Bal Pharma Limited**

**Shailesh Siroya  
Managing Director.**



CORPORATE OFFICE : 5th Floor, Lakshmi Narayan Complex, 10/1, Palace Road, Bengaluru - 560 052. India

Ph. : 91 - 80 - 41379500 Fax : 91 - 80 - 22354057/48

Email : [info@balpharma.com](mailto:info@balpharma.com) Website : [www.balpharma.com](http://www.balpharma.com)

CIN # L85110KA1987PLC008368

REGD. OFFICE & FACTORY : 21 & 22, Bommasandra Industrial Area, Bengaluru - 560 099. Ph: 41570813/19 Fax : 41570820



13	Net Profit / Loss for the period	152.06	266.44	201.46	477.66	457.94	280.60	-25.16	87.11	115.42	108.89	322.90	25.94
14	Minority interest	-	-	-	-	-	-	-85.95	-87.91	-73.42	-177.49	-132.35	-114.60
15	Net Profit / Loss after taxes and minority interest	152.06	266.44	201.46	477.66	457.94	280.60	60.78	175.02	189.05	286.38	455.26	140.54
16	Paid-up Equity Share capital( face value of Rs 10 e	1,417.24	1,417.24	1,287.24	1,417.24	1,287.24	1,287.24	1,417.24	1,417.24	1,287.24	1,417.24	1,287.24	1,287.24
17	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year												
18	Earnings Per Share (of Rs 10 each) (Not annualised )												
a)	Basic	1.07	0.80	1.57	3.37	3.44	2.18	0.43	0.12	1.52	0.77	1.73	1.73
b)	Diluted	1.07	0.80	1.57	3.37	3.44	2.18	0.43	0.12	1.52	0.77	1.73	1.73

**PART II**

<b>A Particulars of Shareholding</b>													
<b>1) Public shareholding</b>													
- Number of Shares													
- Percentage of shareholding													
<b>2) Promoters &amp; Promoter group Shareholding</b>													
<b>a) Pledged / Encumbered</b>													
- Number of Shares													
- Percentage of shareholding													
<b>b) Non-encumbered</b>													
- Number of Shares													
- Percentage of shares (as a % of total shareholding of promoter and promoter group)													
- Percentage of shareholding (as a % of total share capital of the company)													
78,86,570	78,86,570	65,86,570	78,86,570	65,86,570	65,86,570	65,86,570	65,86,570	78,86,570	78,86,570	65,86,570	78,86,570	65,86,570	65,86,570
55.65	55.65	51.17	55.65	51.17	51.17	51.17	51.17	55.65	55.65	51.17	55.65	51.17	51.17
62,85,802	62,85,802	62,85,802	62,85,802	62,85,802	62,85,802	62,85,802	62,85,802	62,85,802	62,85,802	62,85,802	62,85,802	62,85,802	62,85,802
100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
44.35	44.35	48.83	44.35	48.83	48.83	48.83	48.83	44.35	44.35	48.83	44.35	48.83	48.83

**PART III**

<b>B Investor Complaints</b>	
Pending at the beginning of the quarter	Nil
Received during the quarter	Nil
Disposed of during the quarter	Nil
Remaining unresolved at the end of the quarter	Nil

**Notes:**

- 1 The above unaudited financial results as reviewed by the audit committee were approved by the Board of Directors at its meeting held on 07th February 2017.
- 2 Statutory auditors have conducted limited review on the unaudited financial results for the quarter ended 31.12.16
- 3 Previous year figures were regrouped/rearranged to conform to the classification of current year.
- 4 As the company deals with single product i. e pharmaceuticals, segment wise figures are not furnished.

Bangalore  
07-02-2017

By order of the Board of Directors

Foysal Pharma limited



Shailesh Siroya

Managing Director



# T D JAIN AND D I SAKARIA

CHARTERED ACCOUNTANTS

**CA T.D. JAIN** B.Com., F.C.A.  
**CA DHANPAL I SAKARIA**  
B.Com., F.C.A.

# 34, Keshava Nivas, 3rd Floor  
First Main, Gandhinagar  
Bangalore-560 009  
Phone : 22356135, 22356137  
Telefax : 080-22356136  
E-mail : ostawaljain@gmail.com

LIMITED REVIEW REPORT ON THE STANDALONE UNAUDITED FINANCIALS RESULTS  
FOR THE QUARTER ENDED DECEMBER 31, 2016

To  
Board of Directors  
Bal Pharma Limited


We have reviewed the unaudited financial results of BAL PHARMA LIMITED ("the company") for the quarter and nine months ended 31 December, 2016 which are included in the accompanying statement of unaudited financial results for the quarter ended December 31 2016 together with the notes thereon (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes. The Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE)2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.

A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results, prepared in accordance with the applicable Accounting Standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s T D JAIN AND D I SAKARIA  
Chartered Accountants  
Firm registration no: 002491S

  
T D JAIN  
Partner  
M No: 012034

Place: Bangalore  
Date: 06.02.2017





# T D JAIN AND D I SAKARIA

CHARTERED ACCOUNTANTS

**CA T.D. JAIN** B.Com., F.C.A.  
**CA DHANPAL I SAKARIA**  
B.Com., F.C.A.

# 34, Keshava Nivas, 3rd Floor  
First Main, Gandhinagar  
Bangalore-560 009  
Phone : 22356135, 22356137  
Telefax : 080-22356136  
E-mail : ostawaljain@gmail.com

LIMITED REVIEW REPORT ON THE CONSOLIDATED UNAUDITED FINANCIALS RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2016

To  
Board of Directors  
Bal Pharma Limited

We have reviewed the consolidated unaudited financial results of BAL PHARMA LIMITED ("the company") and its subsidiaries (hereafter referred to as the "Group") for the quarter and Nine months ended 31 December 2016 which are included in the accompanying Unaudited Consolidated Financial results for the quarter ended December 31 2016 together with the notes thereon (the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes. The Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.

The statement includes the financial results of following entities:


Lifezen Healthcare Private Limited	Subsidiary
Balance Clinics LLP	Subsidiary
Bal Research Foundation	Subsidiary

We conducted our review in accordance with the Standard on Review Engagement (SRE)2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.

A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of consolidated unaudited financial results, prepared in accordance with the applicable Accounting Standards and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s T D JAIN AND D I SAKARIA  
Chartered Accountants  
Firm registration no: 002491S

  
T D JAIN  
Partner  
M No: 012034

Place: Bangalore  
Date: 06.02.2017

